Search results
Showing 7141 to 7155 of 7701 results
Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis (TA35)
This guidance has been updated and replaced by NICE technology appraisal guidance 373.
This guidance has been updated and replaced by NICE technology appraisal guidance 604.
The guidance has been withdrawn because Janssen withdrew their marketing authorisation on 1 May 2018. The availability of direct-acting antiviral combination treatments for hepatitis C has reduced the use of simeprevir, so the company has decided to discontinue it.
This appraisal has been withdrawn. This is because the marketing authorisation for sipuleucel-T was withdrawn on 19 May 2015.
Beta interferon and glatiramer acetate for the treatment of multiple sclerosis (TA32)
This guidance has been updated and replaced by NICE technology appraisal guidance 527.
This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.
This guidance has been replaced by NICE technology appraisal guidance 91.
This guidance has been updated and replaced by NICE technology appraisal guidance 375.
This guidance has been updated and replaced by NICE guideline NG219.
Pirfenidone for treating idiopathic pulmonary fibrosis (TA282)
This guidance has been updated and replaced by NICE technology appraisal guidance 504.
This guidance has been updated and replaced by NICE technology appraisal guidance 340.
Bosutinib for previously treated chronic myeloid leukaemia (TA299)
This guidance has been updated and replaced by NICE technology appraisal guidance 401.
This guidance has been replaced by NICE technology appraisal guidance 55.
This guidance has been replaced by NICE guideline CG81.
Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (TA289)
This guidance has been updated and replaced by NICE technology appraisal guidance 386.